HOME > BUSINESS > Zydus Cadila has an excellent quarter in Q2, PAT up 33%

Zydus Cadila has an excellent quarter in Q2, PAT up 33%

Pharma giant Zydus Cadila reported excellent numbers for the September quarter, led by rising US revenue that lifted its margins and profits.

For the second quarter ended September 30, 2017, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 857 crores, up by 68% y-o-y.

Net profit was up 33% to Rs. 503 crores

This was due to a sharp increase in revenue. Even as revenue increased by Rs 835 cr on year, total operating expenses including depreciation increased by only about Rs 550 cr, boosting margins.

The total income from operations rose 35% y-o-y to Rs. 3,234 crores.

The company’s business in the US posted sales of Rs. 1,644 crores, up by 66%.

The India formulations business posted sales of Rs. 895 crores, up by 15% excluding the excise duty.

During the quarter, the company launched 4 new products in the US including Mesalamine Delayed Release 1.2 g tablets (generic version of Lialda) with a 180 days exclusivity and received approval for 32 new products, including the generic version of Asacol HD (Mesalamine DR 800 mg tablets) and the generic version of Tamiflu suspension (Oseltamivir Powder for Oral Suspension 6 mg/ml).

The company filed 9 additional ANDAs with the USFDA, during the quarter.

The company launched 25 new products including line extensions in India during the quarter with 5 first in India launches. The company’s business in the emerging markets grew by 16%.

It also announced the initiation of a phase II trial investigating ZYAN1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIFPHI), as a treatment for anemia associated with chronic kidney disease (CKD), during the quarter.

Follow ULTRA.news
Adani Enterprises Q3 operating profit up 49% Diversified group Adani Enterprises reported revenue of Rs 9,938 crores for the Oct-Dec quarter compared to Rs 8,606 crores for the same quarter last year. Due to the higher revenue, operating profit (EBIDTA) jumped to Rs 1,048 crores from Rs 705 crores last year. Net prof...
DB Corp advertising sales down 6% in Oct-Dec North Indian newspaper publisher DB Corp reported disappointing results for the third quarter as its key revenue sources, advertising, saw a abnormal decline during the quarter. Revenue from print advertisements declined by 5.8% despite the comparison being with a quarter that...
Panacea Biotech, Serum Institute in polio vaccine tie-up Panacea Biotec said it signed two long-term agreements with the world's largest vaccine manufacturer, Serum Institute of India Pvt. Ltd, for manufacturing polio vaccines with a potential market size of $1.25 bln per year. The vaccine will also protect against six other diseas...
HUL sees strong growth in profit margins in Q3 Hindustan Unilever, the country's largest fast-moving consumer goods maker, reported a 17% increase in its like-to-like top line and an 11% growth in sales volumes for the October December period when compared to the previous year. The previous year's sales were disrupted by ...
Zee Entertainment reports a 30% jump in India ad sales due to demonetization Zee Entertainment Enterprises, the country's largest listed media company, reported a whopping 30% jump in advertising sales in India as the comparison period of last year was hit by demonetization. Domestic advertising revenue was at Rs 11,373 mn (Rs 1,137 cr) on a like to l...
Ipca Laboratories acquires US pharma manufacturer for $9.65 mln Ipca Laboratories Ltd said it is has acquired US-based drug manufacturer Pisgah Labs Inc. for US$ 9.65 millions free of debt. The acquisition is aimed at establishing the company's foothold in the US market in the field of contract research and small-volume manufacturing of a...
TV18 posts 8% top line growth, regional news slips Reliance Industries' controlled TV18 reported better results than in recent quarters, and said advertising revenue is showing signs of recovery. The company reported a 8% growth in the top line for Oct-Dec quarter to Rs 271 cr, while profit before tax remained flat at Rs 16 c...
Infosys reports in-line quarter, revenue up 5.8% YoY in constant currency Infosys reported a quarter that was largely in line with expectations and said it retains its full-year revenue growth guidance at 5.5-6.5%, excluding the impact of currency movements. With nine months gone, the company has grown at 5.6% in constant currency terms so far. F...
TCS reports 1.2% sales growth QoQ, PAT up 1.3% TCS CEO, Tata Group Chairman & Maharashtra CM Tata Consultancy Services reported a 1.3% improvement in revenue in constant currency terms, which is less than the 1.7% improvement reported in the previous quarter, but largely in line with expectations for a tame quarter. R...
Hindustan Media Ventures reports 5% ad revenue growth Hindustan Media Ventures, the publisher of Hindustan daily, reported a 12% jump in net profit for the third quarter due to ongoing cost cutting measures. On a positive note, advertising revenue increased by Rs 8 cr, or 5%, on year during the third quarter to Rs 177 cr. Howeve...
Glenmark launches anti-inflammation drug based on Adalimumab Glenmark enters Adalimumab market Glenmark Pharmaceuticals said it has launched a biosimilar of Adalimumab, a drug for Plaque Psoriasis and Rheumatoid Arthritis from Cadila Healthcare Ltd.. "The launch of ADALY marks the launch of Glenmark’s first biosimilar in Dermatology...
Titan jewelry retail sales meet expectations, primary sales slow Titan's promotion for Taneira Titan Co, India's largest jewelry company, said its mainstay jewelry business saw retail sales that were in line with expectations for the October-December period, but there was a slight slowdown in sales to franchisees. It also said its pilot...
OrbiMed Asia invests $7.5 mln more in Vivimed Labs unit Vivimed Labs said it will receive $7.5mn investment from OrbiMed Asia into its API business as a follow on to the $42.5 mn invested in September 2017. At the time, Vivimed has said that the proceeds will be utilised for debt reduction at the parent entity level as well as for...
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Sun Pharma’s eye drug application accepted by USFDA Sun Pharmaceutical Industries Ltd said the US FDA has accepted a New Drug Application (NDA) for its OTX-101 dry eye drug. The application will now be processed for approval. Dry eye is a condition in which the eye does not produce tears properly, or when the tears are not of t...
Suven gets neuro drug patents in India, Canada Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are consider...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited. The facility is spread across 12 acres and has a capacity of about 197 KL, the company said. The plant was inspected by the USFDA in 2015, ...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash. "We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences. Last month, Strides Shasun said it was sel...